NASDAQ:CODX
Co-Diagnostics, Inc.
Co-Diagnostics, Inc.'s revenue fell 84.1% in fiscal 2025 to $622,489 while operating margin fell to −8058.8%. Free cash flow was −$29.8M, −4793.2% of revenue, and the diluted share count rose 31.5%.Summary generated from Co-Diagnostics, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$622,489
Revenue growth−84.1%
Revenue, 5-yr CAGR−61.6%
Gross margin64.3%
Operating margin−8058.8%
Net margin−7533.6%
ROICn/a
Return on equity−125.9%
Debt / equityn/a
Free cash flow−$29.8M
FCF margin−4793.2%
Share count change+31.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 98 | 34 | 7 | 4 | 1 |
| Operating income | 46 | −27 | −43 | −40 | −50 |
| Net income | 37 | −14 | −35 | −38 | −47 |
| Free cash flow | 40 | 5 | −23 | −30 | −30 |
Recent filings
- 8-KResults of a shareholder vote
Oct 5, 2026 - 8-KResults of a shareholder vote
Sep 25, 2026 - 8-KRegulation FD disclosure
Sep 16, 2026 - 8-KOther events
Sep 16, 2026 - 8-KOther events
Sep 15, 2026 - 8-KDirector or officer change
Sep 4, 2026 - 8-KResults of a shareholder vote
Sep 4, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026